Business Context and Reporting Period
This Form 8-K reports the results of the 2023 Annual Meeting of Stockholders held by Capricor Therapeutics, Inc. on June 12, 2023. The meeting took place at the company's principal executive offices in San Diego, California.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Stockholders representing 16,347,859 shares (of 25,269,926 entitled to vote) participated in the meeting. The following proposals were voted upon:
- Election of Directors: All seven nominees (Frank Litvack, Linda Marbán, David B. Musket, George W. Dunbar, Jr., Louis Manzo, Earl M. (Duke) Collier, Jr., and Karimah Es Sabar) were elected to serve until the 2024 annual meeting.
- Ratification of Auditors: The appointment of Rose, Snyder & Jacobs LLP as the independent registered accounting firm for the fiscal year ending December 31, 2023, was ratified.
- Executive Compensation: The advisory vote on named executive officer compensation was approved.
- Corporate Governance: An amendment to the Certificate of Incorporation regarding officer exculpation was approved.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results.
Investor Verification Checklist
- Verify the final vote counts for the director elections, noting significant "Broker Non-Votes" (approx. 9.39 million shares) which did not affect the outcome but indicate shares held in street name.
- Review the definitive proxy statement filed on April 17, 2023, for detailed biographies of the elected directors and the specific terms of the officer exculpation amendment.
- Confirm the ratification of Rose, Snyder & Jacobs LLP as the auditor for the upcoming fiscal year.
- Note that the "Say on Pay" vote was non-binding advisory, with a significant portion of votes cast against the proposal (2,446,891 against vs. 4,328,964 for).